U.S. House of Representatives Appropriations Committee chair Rosa DeLauro (D-CT) has secured a timeline from the U.S. Food and Drug Administration (FDA) on the rollout of its new breast density notification rule.
The rule will require healthcare providers to notify women if they have dense breasts and if they need additional screenings to find breast cancer.
DeLauro asked the FDA earlier this month for an update. The agency responded that the Mammography Quality Standards Act (MQSA) final rule would be published before the end of the 2022 calendar year or early 2023.
